Predictors of successful primary antegrade wiring in chronic total occlusion percutaneous coronary intervention.

CTO-PCI antegrade wiring chronic total occlusion percutaneous coronary intervention primary antegrade wiring

Journal

The Journal of invasive cardiology
ISSN: 1557-2501
Titre abrégé: J Invasive Cardiol
Pays: United States
ID NLM: 8917477

Informations de publication

Date de publication:
29 Feb 2024
Historique:
medline: 6 3 2024
pubmed: 6 3 2024
entrez: 6 3 2024
Statut: aheadofprint

Résumé

Antegrade wiring is the most commonly used chronic total occlusion (CTO) crossing technique. Using data from the PROGRESS CTO registry (Prospective Global Registry for the Study of Chronic Total Occlusion Intervention; Clinicaltrials.gov identifier: NCT02061436), we examined the clinical and angiographic characteristics and procedural outcomes of CTO percutaneous coronary interventions (PCIs) performed using a primary antegrade wiring strategy. Of the 13 563 CTO PCIs performed at 46 centers between 2012 and 2023, a primary antegrade wiring strategy was used in 11 332 (83.6%). Upon multivariable logistic regression analysis, proximal cap ambiguity (odds ratio [OR]: 0.52; 95% CI, 0.46-0.59), side branch at the proximal cap (OR: 0.85; 95% CI, 0.77-0.95), blunt/no stump (OR: 0.52; 95% CI: 0.47-0.59), increasing lesion length (OR [per 10 mm increase]: 0.79; 95% CI, 0.76-0.81), moderate to severe calcification (OR: 0.73; 95% CI, 0.66-0.81), moderate to severe proximal tortuosity (OR: 0.67; 95% CI, 0.59-0.75), bifurcation at the distal cap (OR: 0.66; 95% CI, 0.59-0.73), left anterior descending artery CTO (OR [vs right coronary artery]: 1.44; 95% CI, 1.28-1.62) and left circumflex CTO (OR [vs right coronary artery]: 1.22; 95% CI, 1.07-1.40), non-in-stent restenosis lesion (OR: 0.56; 95% CI, 0.49-0.65), and good distal landing zone (OR: 1.18; 95% CI, 1.06-1.32) were independently associated with primary antegrade wiring crossing success. The use of antegrade wiring as the initial strategy was high (83.6%) in our registry. We identified several parameters associated with primary antegrade wiring success.

Sections du résumé

BACKGROUND BACKGROUND
Antegrade wiring is the most commonly used chronic total occlusion (CTO) crossing technique.
METHODS METHODS
Using data from the PROGRESS CTO registry (Prospective Global Registry for the Study of Chronic Total Occlusion Intervention; Clinicaltrials.gov identifier: NCT02061436), we examined the clinical and angiographic characteristics and procedural outcomes of CTO percutaneous coronary interventions (PCIs) performed using a primary antegrade wiring strategy.
RESULTS RESULTS
Of the 13 563 CTO PCIs performed at 46 centers between 2012 and 2023, a primary antegrade wiring strategy was used in 11 332 (83.6%). Upon multivariable logistic regression analysis, proximal cap ambiguity (odds ratio [OR]: 0.52; 95% CI, 0.46-0.59), side branch at the proximal cap (OR: 0.85; 95% CI, 0.77-0.95), blunt/no stump (OR: 0.52; 95% CI: 0.47-0.59), increasing lesion length (OR [per 10 mm increase]: 0.79; 95% CI, 0.76-0.81), moderate to severe calcification (OR: 0.73; 95% CI, 0.66-0.81), moderate to severe proximal tortuosity (OR: 0.67; 95% CI, 0.59-0.75), bifurcation at the distal cap (OR: 0.66; 95% CI, 0.59-0.73), left anterior descending artery CTO (OR [vs right coronary artery]: 1.44; 95% CI, 1.28-1.62) and left circumflex CTO (OR [vs right coronary artery]: 1.22; 95% CI, 1.07-1.40), non-in-stent restenosis lesion (OR: 0.56; 95% CI, 0.49-0.65), and good distal landing zone (OR: 1.18; 95% CI, 1.06-1.32) were independently associated with primary antegrade wiring crossing success.
CONCLUSIONS CONCLUSIONS
The use of antegrade wiring as the initial strategy was high (83.6%) in our registry. We identified several parameters associated with primary antegrade wiring success.

Identifiants

pubmed: 38446022
doi: 10.25270/jic/23.00305
doi:

Banques de données

ClinicalTrials.gov
['NCT02061436']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Athanasios Rempakos (A)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.

Michaella Alexandrou (M)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.

Deniz Mutlu (D)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.

James W Choi (JW)

Texas Health Presbyterian Hospital, Dallas, Texas, USA.

Paul Poommipanit (P)

University Hospitals, Case Western Reserve University, Cleveland, Ohio, USA.

Jaikirshan J Khatri (JJ)

Cleveland Clinic, Cleveland, Ohio, USA.

Laura Young (L)

Cleveland Clinic, Cleveland, Ohio, USA.

Philip Dattilo (P)

Medical Center of the Rockies, Loveland, Colorado, USA.

Yasser Sadek (Y)

National Heart Institute, Cairo, Egypt.

Rhian Davies (R)

WellSpan York Hospital, York, Pennsylvania, USA.

Sevket Gorgulu (S)

Biruni University Medical School, Istanbul, Turkey.

Farouc A Jaffer (FA)

Massachusetts General Hospital, Boston, Massachusetts, USA.

Raj Chandwaney (R)

Oklahoma Heart Institute, Tulsa, OK, USA.

Brian Jefferson (B)

Tristar Centennial Medical Center, Nashville, Tennessee, USA.

Baseem Elbarouni (B)

St. Boniface General Hospital, Winnipeg, Manitoba, Canada.

Lorenzo Azzalini (L)

Division of Cardiology, Department of Medicine, University of Washington, Seattle, Washington, USA.

Kathleen E Kearney (KE)

Division of Cardiology, Department of Medicine, University of Washington, Seattle, Washington, USA.

Khaldoon Alaswad (K)

Henry Ford Cardiovascular Division, Detroit, Michigan, USA.

Mir B Basir (MB)

Henry Ford Cardiovascular Division, Detroit, Michigan, USA.

Oleg Krestyaninov (O)

Meshalkin Novosibirsk Research Institute, Novosibirsk, Russia.

Dmitrii Khelimskii (D)

Meshalkin Novosibirsk Research Institute, Novosibirsk, Russia.

Nazif Aygul (N)

Selcuk University, Konya, Turkey.

Nidal Abi-Rafeh (N)

North Oaks Health System, Hammond, Louisiana, USA.

Ahmed Elguindy (A)

Aswan Heart Center, Magdi Yacoub Foundation, Cairo, Egypt.

Omer Goktekin (O)

Memorial Bahcelievler Hospital, Istanbul, Turkey.

Bavana V Rangan (BV)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.

Olga C Mastrodemos (OC)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.

Ahmed Al-Ogaili (A)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.

Yader Sandoval (Y)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.

M Nicholas Burke (MN)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.

Emmanouil S Brilakis (ES)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.

Arun Kalyanasundaram (A)

The Promed Hospital, Chennai, India. Email: arunksundaram@gmail.com.

Classifications MeSH